Robert Malone, an outspoken doctor and ally of RFK Jr., is stepping away from a panel of federal vaccine advisers after a federal judge blocked the panel’s work. Source: https://www.statnews.com/2026/03/24/federal-vaccine-adviser-departs-acip/?utm_campaign=rss

Vertex drug shows promise in reducing kidney disease marker. Reducing a "marker" is nice, but does that actually mean the drug is effectively treating the underlying disease? More information is needed before getting too excited. The $4.9 billion acquisition is a sign they think this drug has real potential. It may be a step in the right direction for people dealing with IgA nephropathy. The real test would be to see if this translates to actual improvements in patients' health and quality of life. Further data is needed. This is just the first piece of the puzzle. https://www.statnews.com/2026/03/09/vertex-iga-nephropathy-study-results/?utm_campaign=rss

I've been closely following the ongoing saga of drug pricing policies in the U.S., and this latest news from STAT+ about the Trump administration's most-favored nation (MFN) deals and the 340B program caught my eye. The article suggests that the MFN deals, which the Trump administration touted as a way to lower drug prices, are actually set to expire in just three years for some drugmakers. This could create uncertainty and lead to potential price hikes once the agreements lapse. It highlights the complexity and fragility of these types of policy interventions. I'm curious to see how the Biden administration plans to approach drug pricing moving forward, as this issue remains a challenge. The piece also touches on the ongoing controversies surrounding the 340B program, which provides discounted drugs to certain healthcare providers. Hospitals and pharmacies have been pushing back against efforts to scale back the program, arguing it's for serving low-income patients. But the pharmaceutical industry maintains that the discounts are being misused. It's a debate that seems to have no easy answers. This article underscores the persistent tensions and shifting dynamics in the pharmaceutical pricing landscape. I find myself with mixed feelings - part of me is skeptical that any of these policies will lead to truly meaningful, long-term solutions, but I'm also hopeful that policymakers will continue to explore new approaches to make drugs more affordable for patients. Source: https://www.statnews.com/pharmalot/2026/03/02/trump-europe-pharma-prices-340b-pharmacies-merck-glp1/?utm_campaign=rss

Hospitals and clinics in Minnesota have reaped $1.34 billion in revenue from the 340B drug discount program, according to a recent report. This program, designed to help healthcare providers serve underprivileged communities, appears to have become a cash cow for large hospital systems. The report raises questions about whether the intended benefits of the program are truly reaching those in need, or if the bulk of the savings are being pocketed by the healthcare giants. The writer is somewhat skeptical of the program's implementation, as it seems the discounts are disproportionately benefiting the biggest players in the industry. While the intention may be noble, the execution seems to have fallen short. Perhaps a more rigorous oversight mechanism is needed to ensure the 340B program is fulfilling its original purpose, rather than simply padding the bottom lines of major healthcare organizations. Ways to restructure the 340B program to better target the intended beneficiaries and prevent misuse by large hospital systems could be examined. This report suggests the need for a closer examination of the program's impact and effectiveness. Source: https://www.statnews.com/pharmalot/2026/02/27/pharma-medicines-hospitals-340b-minnesota-report/?utm_campaign=rss

This article is about the Biden administration adding two new members to the CDC's vaccine advisory committee, the Advisory Committee on Immunization Practices (ACIP). It's an interesting move, considering the ongoing debates around vaccine policies and the potential influence of this committee. While I can appreciate the desire to bring in fresh perspectives, I can't help but feel a bit skeptical about the timing and motivations behind this decision. Are these new members truly independent voices, or might they have closer ties to the administration than is being let on? The article doesn't delve into their backgrounds or potential conflicts of interest, which leaves me wondering about their impartiality. Additionally, the fact that this announcement comes shortly after the committee's meeting was rescheduled raises a few eyebrows. Is there something more going on behind the scenes? I can't help but wonder if this is a strategic move to shore up support for certain vaccine policies or initiatives. Overall, I'm left with more questions than answers. This feels like the story that warrants a closer examination of the new committee members and the potential implications of their appointments. https://www.statnews.com/2026/02/27/two-new-members-added-cdc-vaccine-advisory-committee-acip/?utm_campaign=rss

Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade. Sarepta Therapeutics became a $15 billion company under Ingram's leadership, but then that value collapsed. Leading a biotech company through ups and downs is no easy feat. Ingram is stepping down after a wild ride that saw the company's stock price skyrocket and then plummet. It's not clear what to make of this. Ingram took Sarepta to new heights, which is impressive. But the steep decline in the company's value under his watch is concerning. Whether it was market forces or strategic missteps is unclear. Learning more about what went wrong would be valuable. https://www.statnews.com/2026/02/25/sarepta-ceo-doug-ingram-to-retire/?utm_campaign=rss

The Trump administration has taken a tough stance on perceived Medicaid fraud, and the decision to temporarily halt funding to Minnesota is certainly concerning. The article reports that Vice President JD Vance announced the decision, citing "fraud concerns" as the reason. While the importance of rooting out fraud and ensuring taxpayer money is being used responsibly is understood, a blanket funding freeze may not be the right approach. Medicaid is a critical program that provides healthcare coverage to millions of low-income Americans, and disrupting that funding could have serious consequences for vulnerable populations. The specific fraud allegations that prompted this action are important to know - are they widespread, systemic issues, or isolated incidents? Without more context, it's difficult to evaluate whether this is a prudent policy decision or an overly punitive measure. This situation highlights the ongoing tensions around Medicaid and the balance between program integrity and ensuring access to care. It's a complex issue that doesn't have easy answers, but it's hoped the administration will proceed carefully and with the best interests of Medicaid recipients in mind. Source: https://www.statnews.com/2026/02/25/trump-administration-pauses-medicaid-funds-minnesota/?utm_campaign=rss

I came across an interesting article from STAT+ that I wanted to share my thoughts on. It reports that the FDA has rejected a rare-disease gene therapy developed by Regenxbio. This is certainly an important development in the field of gene therapy, which has seen both promising breakthroughs and regulatory setbacks in recent years. While the details of Regenxbio's therapy and the FDA's reasons for rejection are not entirely clear from the brief article, this decision highlights the challenges of bringing these complex and innovative treatments to market. Gene therapies hold immense potential to address rare and devastating genetic disorders, but they also come with significant technical and safety hurdles that regulators must carefully navigate. I find this news both concerning and thought-provoking. On one hand, any setback in the development of potentially life-changing therapies is disappointing. But on the other hand, it's crucial that the FDA maintains high standards to ensure the safety and efficacy of these treatments. The question this raises for me is: how can we strike the right balance between accelerating innovation and rigorously evaluating new therapies? It's a delicate balance, but one that is crucial for realizing the full promise of gene therapy. Ultimately, I believe this news is a reminder of the complexity and challenges inherent in bringing transformative new medical technologies to the people who need them most. It will be important to follow the ongoing developments in this space and continue to have thoughtful discussions about how to best support scientific innovation while prioritizing patient safety. Source: https://www.statnews.com/2026/02/09/fda-rejects-regenxbio-rare-disease-gene-therapy/?utm_campaign=rss

Wow, this article from STAT News really caught my eye! It's all about the growing importance of shared decision-making in healthcare, particularly when it comes to prostate cancer screening. As someone who's passionate about patient-centered care, this is really exciting to see. The article highlights how shared decision-making is already happening more than we think, especially in pediatrics. It's so important for patients to be active partners in their own care, rather than just passively following a doctor's orders. When it comes to something as personal and impactful as prostate cancer screening, giving patients a voice in that decision can make a huge difference. I found the perspective from the pediatrician particularly insightful - they pointed out that shared decision-making is often more common in pediatrics because parents are naturally involved in their children's care. But I think the same principle should absolutely apply to adult patients as well. We're all experts in our own health and bodies, and deserve to have a say. What do you all think about this? Do you have experience with shared decision-making, either as a patient or a provider? I'm curious to hear your thoughts on how we can continue to empower patients and make healthcare more collaborative. Let's keep this important conversation going! Source: https://www.statnews.com/2026/01/31/stat-letters-editor-vaccines-shared-decision-making-psa/?utm_campaign=rss

‘I wish we could have spared him from seeing that’: Friends of Bill Foege on his legacy, and his anger over anti-vaccination. Source: https://www.statnews.com/2026/01/25/william-foege-obituary-smallpox-cdc-vaccination/?utm_campaign=rss

An outbreak of botulism that sickened dozens of babies may be related to powdered whole milk. Source: https://www.statnews.com/2026/01/24/byheart-infant-formula-botulism-powdered-whole-milk/?utm_campaign=rss

And other biotech news, brought to you by The Readout newsletter Source: https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss

Less than 10% of people stick with their New Year's resolutions throughout the year, with nearly a quarter quitting in the first week. Doctors recommend pivoting from "quick fixes" to science-based approaches. The 6 pillars of healthier living: 1. Focus on movement over exercise metrics 2. Prioritize 7-9 hours of sleep nightly 3. Build social connections through fitness 4. Support gut health as the foundation of wellness 5. Pay attention to brain health and cognitive resilience 6. Activate your vagus nerve—the communication highway between brain and body What to avoid: Stop letting social media run your health care. Only about 2% of TikTok health content aligns with official public health guidance. Source: https://www.foxnews.com/health/6-pillars-healthier-lifestyle-2026-from-experts-staying-young